TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07493122: A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes

Sponsor: Immunocore Ltd · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 154 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07493122 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07493122 Rescue Dossier →